This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Odenholt, I.
Right arrow Articles by Cars, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Odenholt, I.
Right arrow Articles by Cars, O.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2002, p. 2046-2048, Vol. 46, No. 6
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.6.2046-2048.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Pharmacodynamics of Moxifloxacin against Streptococcus pyogenes in an In Vitro Kinetic Model

Inga Odenholt,* Elisabeth Löwdin, Ingegerd Gustafsson, and Otto Cars

Antibiotic Research Unit, Department of Infectious Diseases and Clinical Microbiology, University Hospital, Uppsala, Sweden

Received 22 May 2001/ Returned for modification 14 November 2001/ Accepted 26 February 2002

The aim of the present study was to investigate the pharmacodynamics of moxifloxacin against strains of Streptococcus pyogenes with different susceptibilities to erythromycin by using an in vitro kinetic model simulating human pharmacokinetics of moxifloxacin at oral doses of 400 and 200 mg, respectively. When the different strains of S. pyogenes were exposed to the higher dose, the number of bacteria was reduced below the detection limit after 12 h and no regrowth was noted during the following 12 h. At the lower dose there was regrowth of the strains with constitutive and inducible erythromycin resistance of the MLSB phenotype. Replication assays of the regrowing bacteria indicated that the failure of moxifloxacin to kill the MLSB strains at the lower dose was likely caused by the emergence of preexisting resistant subpopulations. Thus, the present study indicates that the presently used 400-mg dose seems to have an advantage over the lower dose in that the risk for selection of resistant subpopulations is minimized.

* Corresponding author. Mailing address: Department of Infectious Diseases, University Hospital, MAS S-20502 Malmö, Sweden. Phone: (46) 40-331806. Fax: (46) 40-336279. E-mail: inga.odenholt{at}inf.mas.lu.se.

Antimicrobial Agents and Chemotherapy, June 2002, p. 2046-2048, Vol. 46, No. 6
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.6.2046-2048.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Singh, R., Ledesma, K. R., Chang, K.-T., Hou, J.-G., Prince, R. A., Tam, V. H. (2009). Pharmacodynamics of moxifloxacin against a high inoculum of Escherichia coli in an in vitro infection model. J Antimicrob Chemother 64: 556-562 [Abstract] [Full Text]  
  • Odenholt, I., Cars, O. (2006). Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model. J Antimicrob Chemother 58: 960-965 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»